Compound anticancer sustained-release injection containing clofarabine
A slow-release injection and compound technology, applied in the field of compound anti-cancer drug slow-release, slow-release injection and slow-release implants, can solve the problem of local formation of effective drug concentration in difficult tumors, accelerate tumor spread and metastasis, and effectively affect cost. implementation and other issues to achieve the effect of facilitating drug injection, reducing complications and reducing costs
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Examples
Embodiment 1
[0124] Put 80 mg of polylactic acid (PLGA) with a peak molecular weight of 25,000 into a container, add 100 ml of dichloromethane, dissolve and mix well, add 10 mg of clorabine and 10 mg of gemcitabine, re-shake, and then vacuum-dry to remove the organic solvent. The dried solid composition is shaped immediately, subpackaged and then sterilized by radiation to obtain the anticancer slow-release product containing 10% clorabine and 10% gemcitabine. All are percentages by weight. The drug release time of the anti-solid tumor pharmaceutical composition in physiological saline in vitro is 14-21 days, and the drug release time in mouse subcutaneous is 25-45 days.
Embodiment 2
[0126] As described in Example 1, the difference is that the anticancer active ingredient and weight percentage are one of the following:
[0127] (a) 2-40% clorabine and 2-40% bleomycin, daunorubicin, diethoxyacetamicin, nocardin, nocardioerythrin, nocardia-type Mycin, Nogamycin, Mitomycin, Polymyxin E, Pilimycin, Dirithromycin, Antramycin, Pelomycin, Puromycin, Spamycin, Anthracene Caminomycin, Caminomycin, Puromycin, Alarubicin, Aclarubicin-B, Idarubicin, Serpentin, Clarithromycin, Adazol Hydrochloride, Adazol, Combinations of doxorubicin, epirubicin, valrubicin, pirarubicin, loxantrone, loxoxantrone, mitoxantrone, pyroxantrone, tiloxantrone, or clozocin ;or
[0128] (b) 2-40% clorabine and 2-40% pemetrexed, pemetrexed disodium, lumitrexed, carmofur, tegafur, temozolomide, zalcitabine, Tritabine, gallocitabine, ibacitabine, ancitabine, decitabine, flucitabine, enoxitabine, midazitabine, capecitabine, gemcitabine, fludarabine, radium A combination of tetrozan, raltitrexe...
Embodiment 3
[0131] Put 80mg polyphenylene propane (p-CPP: sebacic acid (SA) at 20:80) copolymer into a container, add 100ml dichloromethane, dissolve and mix well, then add 10mg Rorabine and 10 mg doxorubicin were re-shaken and spray-dried to prepare microspheres for injection containing 10% clorabine and 10% doxorubicin. Then suspend the microspheres in physiological saline containing 15% mannitol to prepare the corresponding suspension-type sustained-release injection with a viscosity of 20cp-300cp (at 20°C-30°C). The drug release time of the slow-release injection in physiological saline in vitro is 10-15 days, and the drug release time in mice subcutaneous is about 20-30 days.
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com